Fulvestrant
- Generic Name
- Fulvestrant
- Brand Names
- Faslodex, Fulvestrant Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C32H47F5O3S
- CAS Number
- 129453-61-8
- Unique Ingredient Identifier
- 22X328QOC4
- Background
Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatment of breast cancers, it is also used in combination with alpelisib for the treatment of HR-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer
- Indication
For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors
- Conditions
- HER2-negative Breast CancerBreast CancerUnresectable Solid TumorPIK3CA MutationSolid Tumor, AdultHormone Receptor Positive TumorMetastatic Breast CancerAdvanced Breast Cancer
- Interventions
- First Posted Date
- 2023-03-08
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Relay Therapeutics, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT05759949
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Community Cancer Center North, Indianapolis, Indiana, United States
🇺🇸Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
- Conditions
- Breast CancerBreast Cancer MetastaticHormone Receptor Positive TumorHuman Epidermal Growth Factor 2 Negative Carcinoma of BreastOvarian CancerAdvanced CancerCCNE1 AmplificationSolid TumorMetastatic Cancer
- Interventions
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Incyclix Bio
- Target Recruit Count
- 150
- Registration Number
- NCT05735080
- Locations
- 🇺🇸
Georgia Cancer Center at Augusta University, Augusta, Georgia, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸UTSW Medical Center, Dallas, Texas, United States
Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC
- Conditions
- Metastatic Breast CancerPremenopausal Breast CancerER Positive Breast Cancer
- Interventions
- First Posted Date
- 2023-02-09
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT05720260
- Locations
- 🇨🇳
Department of Oncology, National Taiwan University Hospital, Taipei City, Taiwan
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2023-01-25
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Sermonix Pharmaceuticals Inc.
- Target Recruit Count
- 500
- Registration Number
- NCT05696626
- Locations
- 🇨🇳
The First Hospital of Lanzhou University, Lanzhou, China
🇨🇳Linyi Cancer Hospital, Linyi, China
🇨🇳The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
- Conditions
- Advanced Breast Cancer
- Interventions
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 624
- Registration Number
- NCT05654623
- Locations
- 🇺🇸
Morton Plant Hospital - BayCare Health System, Clearwater, Florida, United States
🇺🇸3T Radiology LLC, Coconut Creek, Florida, United States
🇺🇸Florida Cancer Specialists - South, Fort Myers, Florida, United States
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2022-12-12
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 400
- Registration Number
- NCT05646862
- Locations
- 🇦🇷
Clinica Viedma S.A., Viedma, Argentina
🇨🇳The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou City, China
🇨🇳Sir Run Run Shaw Hospital Zhejiang University, Hangzhou City, China
Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment
- First Posted Date
- 2022-11-30
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 100
- Registration Number
- NCT05631795
- Locations
- 🇮🇳
Novartis Investigative Site, New Delhi, India
VS-6766+Abema+Fulv in Met HR+/HER- BC
- Conditions
- Breast CancerHormone Receptor Positive HER-2 Negative Breast CancerHormone Receptor-positive Breast Cancer
- Interventions
- First Posted Date
- 2022-11-08
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Adrienne G. Waks
- Target Recruit Count
- 63
- Registration Number
- NCT05608252
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institite, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2022-11-01
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 484
- Registration Number
- NCT05601440
- Locations
- 🇨🇦
Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta, Canada
🇨🇦Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
🇨🇦Odette Cancer Centre, Toronto, Ontario, Canada
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
- Conditions
- HER2-negative Breast CancerAdvanced Breast CancerBreast NeoplasmBreast CancerHormone Receptor Positive Tumor
- Interventions
- Drug: AKT inhibitorDrug: CarrelizumabDrug: SHR-1167Drug: TPCDrug: SHR-6209
- First Posted Date
- 2022-10-26
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 620
- Registration Number
- NCT05594095
- Locations
- 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.